Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Advances in OncologyAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- The landscape of kinase fusions in cancer.Nat Commun. 2014; 5: 4846
- NTRK fusion detection across multiple assays and 33,997 cases: diagnostic implications and pitfalls.Mod Pathol. 2020; 33: 38-46
- Neurotrophin-regulated signalling pathways.Philos Trans R Soc Lond B Biol Sci. 2006; 361: 1545-1564
- A human oncogene formed by the fusion of truncated tropomyosin and protein tyrosine kinase sequences.Nature. 1986; 319: 743-748
- Genomic context of NTRK1/2/3fusion-positive tumours from a large real-world population.NPJ Precis Onc. 2021; 5: 86https://doi.org/10.1038/s41698-021-00206-y
- Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials.Lancet Oncol. 2020; 21: 531-540
- Efficacy of Larotrectinib in TRK fusion-positive cancers in adults and children.N Engl J Med. 2018; 378: 731-739
- Safety and antitumor activity of the multitargeted Pan-TRK, ROS1, and ALK inhibitor entrectinib: combined results from two phase I trials (ALKA-372-001 and STARTRK-1).Cancer Discov. 2017; 7: 400-409
- U.S. phase I first-in-human study of Taletrectinib (DS-6051b/AB-106), a ROS1/TRK inhibitor, in patients with advanced solid tumors.Clin Cancer Res. 2020; 26: 4785-4794
- MA11.07 Phase 1/2 TRIDENT-1 study of repotrectinib in patients with ROS1+ or NTRK+ advanced solid tumors.J Thorac Oncol. 2021; 16
- Neurotrophin signal transduction in the nervous system.Curr Opin Neurobiol. 2000; 10: 381-391
- Functions of the neurotrophins during nervous system development: what the knockouts are teaching us.Cell. 1994; 77: 627-638
- A comprehensive p75 neurotrophin receptor gene network and pathway analyses identifying new target genes.Sci Rep. 2020; 10: 14984https://doi.org/10.1038/s41598-020-72061-z
- NTRK fusion-positive cancers and TRK inhibitor therapy.Nat Rev Clin Oncol. 2018; 15: 731-747
- TrkA Immunoglobulin-like ligand binding domains inhibit spontaneous activation of the receptor.Mol Cell Biol. 2020; 20: 5908-5916
- NTRK kinase domain mutations in cancer variably impact sensitivity to type I and type II inhibitors.Commun Biol. 2020; 3: 776https://doi.org/10.1038/s42003-020-01508-w
- TRKing down an old oncogene in a new era of targeted therapy.Cancer Discov. 2015; 5: 25-34
- Congenital insensitivity to pain with anhidrosis: novel mutations in the TRKA (NTRK1) gene encoding a high-affinity receptor for nerve growth factor.Am J Hum Genet. 1999; 64: 1570-1579
- The TPM3-NTRK1 rearrangement is a recurring event in colorectal carcinoma and is associated with tumor sensitivity to TRKA kinase inhibition.Mol Oncol. 2014; 8: 1495-1507
- Identification and characterization of an activating TrkA deletion mutation in acute myeloid leukemia.Mol Cell Biol. 2000; 20 (2000) 8655-8666)
- Trka alternative splicing: a regulated tumor-promoting switch in human neuroblastoma.Cancer Cell. 2004; 6: 347-360
- What hides behind the MASC: clinical response and acquired resistance to entrectinib after ETV6-NTRK3 identification in a mammary analogue secretory carcinoma (MASC).Ann Oncol. 2016; 27: 920-926
- NTRK fusions, from the diagnositc algorithm to innovative treatment in the era of precision medicine.Int J Mol Sci. 2020; 21: 3718
- NTRK gene rearrangements are highly enriched in MLH1/PMS2 deficient, BRAF wild-type colorectal carcinomas-a study of 4569 cases.Mod Pathol. 2020; 33: 924-932
- An in vivo functional genetic screen reveals a role for the TRK-T3 oncogene in tumor progression.Oncogene. 2004; 23: 4959-4965
- A systematic analysis of oncogenic gene fusions in primary colon cancer.Cancer Res. 2017; 77: 3814-3822
- TRK fusions are enriched in cancers with uncommon histologies and the absence of canonical driver mutations.Clin Cancer Res. 2020; 26: 1624-1632
- An oncogenic NTRK fusion in a patient with soft-tissue sarcoma with response to the tropomyosin-related kinase inhibitor LOXO-101.Cancer Discov. 2015; 5: 1049-1057
- Entertain, a Pan–TRK, ROS1, and ALK inhibitor with activity in multiple molecularly defined cancer indications.Mol Cancer Ther. 2016; 15: 628-639
- Entrectinib: an orally available, selective tyrosine kinase inhibitor for the treatment of NTRK, ROS1, and ALK fusion-positive solid tumors.Ther Clin Risk Manag. 2018; 14: 1247-1252
- FDA approves larotrectinib for solid tumors with NTRK gene fusions.(Available from) (Accessed August 29, 2021)
- FDA approves entrectinib for NTRK solid tumors and ROS-1 NSCLC.(Available from) (Accessed August 29, 2021)
- Sensitivity to Entrectinib associated With a Novel LMNA-NTRK1 gene fusion in metastatic colorectal cancer.J Natl Cancer Inst. 2016; 108https://doi.org/10.1093/jnci/djv306
- Durable clinical response to entrectinib in NTRK1-rearranged non-small cell lung cancer.J Thorac Oncol. 2015; 10: 1670-1674
- TRK inhibitors in TRK fusion-positive cancers.Ann Oncol. 2019; 30: viii23-viii30
- Acquired resistance to the TRK inhibitor entrectinib in colorectal cancer.Cancer Discov. 2016; 6: 36-44
- A next-generation TRK kinase inhibitor overcomes acquired resistance to prior TRK kinase Inhibition in patients with TRK fusion-positive solid tumors.Cancer Discov. 2017; 7: 963-972
- Repotrectinib (TPX-0005) Is a Next-Generation ROS1/TRK/ALK Inhibitor That Potently Inhibits ROS1/TRK/ALK Solvent- Front Mutations.Cancer Discov. 2018; 8: 1227-1236
- The new-generation selective ROS1/NTRK inhibitor DS-6051b overcomes crizotinib resistant ROS1-G2032R mutation in preclinical models.Nat Commun. 2019; 10: 3604
- Phase I and expanded access experience of LOXO-195 (BAY 2731954), a selective next-generation TRK inhibitor (TRKi).in: Proceedings of the 110th Annual meeting of the american association for cancer research; 2019. AACR, Atlanta, GA. Philadelphia (PA)2019 (Abstract nr CT127)
- Mechanisms of resistance to NTRK inhibitors and therapeutic strategies in NTRK1-rearranged cancers.Mol Cancer Ther. 2017; 16: 2130-2143
- Monitoring of cancer patients via next-generation sequencing of patient-derived circulating tumor cells and tumor DNA.Cancer Sci. 2019; 110: 2590-2599
- Resistance to TRK inhibition mediated by convergent MAPK activation.Nat Med. 2019; 25: 1422-1427
- ABCB1 and ABCG2 restrict brain and testis accumulation and, alongside CYP3A, limit oral availability of the novel TRK inhibitor selitrectinib.Mol Cancer Ther. 2021; 20: 1173-1182
Article info
Identification
Copyright
© 2022 Elsevier Inc. All rights reserved.
